Prenatal Screening and Assessment

Prenatal screening and assessment is the set of tests offered during pregnancy to estimate the probability that the fetus is affected by a chromosomal aneuploidy or a structural anomaly. It combines maternal characteristics, biochemical markers, ultrasound findings, and, increasingly, cell-free DNA analysis to sort pregnancies into higher- and lower-risk groups, with positive screens directed toward diagnostic confirmation.

Definition

Prenatal screening is the assessment, during pregnancy, of the probability that a fetus is affected by a chromosomal or structural anomaly, using maternal, biochemical, ultrasound, and cell-free DNA information to identify pregnancies for which diagnostic testing may be offered.

Scope

The topic covers the principal prenatal screening modalities and their logic: maternal serum biochemical screening, ultrasound-based markers, combined first-trimester screening, and noninvasive prenatal screening using cell-free DNA. It addresses how these screens relate to the diagnostic tests that confirm or exclude a condition, and the concepts of detection rate, false-positive rate, and informed choice. It does not provide protocols for managing an affected pregnancy.

Core questions

• How do biochemical, ultrasound, and cell-free DNA methods estimate the risk of fetal aneuploidy?
• Why is prenatal screening distinct from prenatal diagnosis, and when is diagnostic testing offered?
• How are detection rate and false-positive rate balanced, and how is informed choice preserved?

Key concepts

• Maternal serum screening
• Combined first-trimester screening
• Cell-free DNA (noninvasive prenatal) screening
• Detection rate and false-positive rate
• Screening versus diagnostic testing
• Confirmatory diagnostic testing
• Informed choice and counselling

Mechanisms

Prenatal screening integrates multiple sources of information into an individualised risk estimate. Biochemical screening measures analytes in maternal serum whose concentrations shift in affected pregnancies; ultrasound contributes markers such as nuchal translucency; and these are combined with maternal age and gestational age to compute a risk. Cell-free DNA screening instead analyses placental DNA fragments circulating in maternal blood, counting or sequencing them to detect the relative excess associated with a trisomy, achieving higher detection rates for common aneuploidies than earlier serum approaches. Because all of these are screening tests, a high-risk result is followed by diagnostic testing on fetal material before any condition is confirmed.

Clinical relevance

Prenatal screening shapes the information available to prospective parents and clinicians during pregnancy, and appraising it supports understanding of why specific tests are offered and what their results do and do not establish. This entry describes how prenatal screening operates as a program; it is a reference description and not a basis for individual diagnostic or management decisions.

Epidemiology

Aneuploidy screening is offered routinely in pregnancy care in many health systems. The target conditions, such as trisomy 21, are individually uncommon and their baseline probability rises with maternal age, which is why screening combines population markers with individual risk factors and why the positive predictive value of a screen depends on the underlying prevalence.

History

Prenatal screening for fetal anomaly began with the observation that maternal serum alpha-fetoprotein and related analytes differ in affected pregnancies, formalised in the 1980s as serum screening for Down syndrome. Combined first-trimester screening added ultrasound markers, and from around 2011 cell-free DNA analysis introduced a screening method with markedly higher detection rates for common trisomies, as quantified in large general-obstetric cohorts such as Norton and colleagues' 2015 study.

Debates

Should cell-free DNA screening replace combined first-trimester screening as the primary test?

Cell-free DNA screening offers higher detection and lower false-positive rates for common trisomies, but cost, scope of conditions detected, and the management of no-call and discordant results inform whether it is offered as first-line or contingent screening.

Key figures

• Nicholas Wald
• Howard Cuckle
• Mary Norton

Seminal works

• cuckle-1984
• norton-2015

Frequently asked questions

Does a positive prenatal screening result mean the fetus has the condition?

No. A high-risk screening result indicates increased probability, not a diagnosis. Diagnostic testing on fetal material is needed to confirm or exclude the condition.

How does cell-free DNA screening differ from serum screening?

Serum screening uses maternal analytes and ultrasound combined with age to estimate risk, while cell-free DNA screening analyses placental DNA fragments in maternal blood, generally achieving higher detection rates for common trisomies.